TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology
TG Therapeutics announced the publication of post-hoc pooled data from its Phase 3 ULTIMATE I and II trials in Frontiers in Immunology. The analysis showed BRIUMVI reduced annualized relapse rates by 56.7% versus teriflunomide in treatment-naïve patients, with an 82.7% NEDA-3 response rate compared to 23.1% for the comparator.
Key figures
- Drug Name
- BRIUMVI (ublituximab-xiiy)
- Phase Of Trial
- Phase 3
- T1 lesion reduction
- 96.1%
- T2 lesion reduction
- 90.6%
- Neda3 rate ublituximab
- 82.7%
- Neda3 rate teriflunomide
- 23.1%
- Arr reduction early treated
- 61.0%
- Arr reduction vs teriflunomide
- 56.7%
- Disability improvement ublituximab
- 10.7%
- Disability improvement teriflunomide
- 5.3%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.